Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U.S. FDA Counts 62 Deaths That Could Be Tied To Chinese Heparin

This article was originally published in PharmAsia News

Executive Summary

The U.S. FDA says it has received 62 reports of deaths that could be tied to Chinese-produced heparin, more than triple the numbers announced previously. The 62 died within the past 15 months of allergic reactions or low blood pressure, symptoms involved with contaminated heparin. The FDA cautions the heparin may not be the cause of death in all cases. Baxter International recalled most of the product in February, but the drug was produced from basic supplies also shipped to other makers of the drug, such as APP Pharmaceuticals, which said its users were not among the 62 listed by the FDA. (Click here for more

You may also be interested in...



U.S. FDA Triples Estimate On Deaths Following Allergic Reaction To Blood Thinner Heparin

BEIJING - U.S. FDA last week issued a sharply higher estimate on the number of deaths that have occurred in patients who suffered allergic reactions to the blood thinner heparin

Fujifilm Demonstrates Health Specialism With European HealthTech Spinout

From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics. 

Financing Quarterly Statistics, Q1 2024

During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel